Skip to content

leadXpro

“We unlock tomorrow’s medicines together, better, faster.”

At leadXpro, we are committed to accelerating the discovery of life-changing medicines. Driven by our passion for innovation and cutting-edge science, we specialize in structure-based drug discovery, with a laser focus on membrane proteins. Working together with our clients, we aim to transform our science into therapies—better and faster.

Core Expertise

Our expertise lies in unlocking the potential of membrane proteins, important yet challenging targets in drug discovery. Through advanced methods such as CryoEM, time resolved X-ray crystallography, and ultra-large virtual screening, we provide a comprehensive platform to support pharmaceutical innovation. From early-stage discovery to lead optimization, we empower researchers to accelerate breakthroughs in medicine.

Track Record

  • Over 10 years of experience in structure-based drug discovery.
  • Delivering Swiss quality over 10 years of experience in structure-based drug discovery.
  • Successfully collaborated on 150+ projects on over 90 different membrane proteins with leading biotech and pharmaceutical companies.
  • Published in top-tier scientific journals, advancing the field of membrane protein research.
Target_Portfolio_Jan2025

Philosophy

At the heart of our work is a commitment to collaboration, excellence, and innovation. We believe success is a shared journey, driven by open communication and diverse perspectives. With unwavering determination, we embrace scientific challenges to deliver impactful results and build lasting partnerships. Excellence is our standard, achieved through continuous improvement, persistence, and precision. By fostering a mindset of innovation and challenging the status quo, we turn scientific discoveries into transformative applications. Together, we strive to make a meaningful impact on structure-based drug discovery for membrane proteins.

Team

Group_Picture_V14-logo-1600px-ppt
Education_Gender_balance_2025

Our state-of-the-art labs

park_innovaare_feature

Our new, state-of-the-art lab, opened in 2024 at Park Innovaare in Villigen, Switzerland, is equipped to support cutting-edge research in protein expression and purification, biophysical assays, crystallization, and grid freezing. With advanced facilities and the latest technologies, we provide a fully integrated environment that accelerates every stage of your research and drug discovery process. Our lab is designed for high throughput and precision, ensuring reliable, high-quality results for your most demanding projects.

lab_feature1
lab_feature2

Founders

LXP_Team_Board_Portraits_G_Schertler-1

Gebhard Schertler

Expert, Membrane Protein Science

Biochemist, department head BIO and member of the Directorial Board of the Paul Scherrer Institue PSI

Michael Henning

Michael Hennig

CEO and Chairman of the Board

Structural biologist and senior drug discovery executive. Previously, global leader discovery technologies at Roche.

Rafael Abela

Rafael Abela

Technology Expert, Board Member

Physicist at the PSI, scientific project leader for the SLS and SwissFEL projects.

Board of Directors

Portrait Michael Milos Web

Michael Milos

Board Member

Molecular Biologist, life-cycle management in drug development at Actelion, project management at Vaxxilon and co-founder of AVANTECA Partners.

Portrait John Millard Web

John Millard

Board Member

Chemical engineering, MBA at London Business School, positions at BP, ABB, Enron and other companies, co-founder of two companies. Since 2018 Head of Technology Transfer Management at PSI.

Andreas Insam

Andreas Insam

Board Member

Doctor in political economics, University of Innsbruck. Previously CEO of Bendura Bank, previously Board member of LGT Bank.

  • Michael Hennig as Chairman of the Board
  • Rafael Abela as Board Member